An observational study in Heart Failure, Atrial Fibrillation and Valvular Heart Disease, sponsored by Tunisian Society of Cardiology and Cardiovascular Surgery. Recruiting at 1 site in Tunisia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-22.
Sponsored by Tunisian Society of Cardiology and Cardiovascular Surgery · Observational
The MEA cardiology societies have joined forces to tackle the issue by establishing a tangible real-world data registry in every MEA country. This endeavor has resulted in the development of a multicenter registry called MEA-WCVD, which is being sponsored by each national cardiology society from participating countries. All data gathered will be consolidated into a singular registry for thorough analysis. Country specific analysis will be performed.
3,870 studies on the registry are indexed under Atrial Fibrillation; 924 are open to participants now.
This study's planned enrollment of 2,000 is above the median of 300 across 1,363 observational studies indexed under Atrial Fibrillation.
Browse Atrial Fibrillation studies →This is the only study on the registry with Tunisian Society of Cardiology and Cardiovascular Surgery as lead sponsor.
Counted across the registry records on this site, refreshed daily.
All patients having their consultation in the study participating site.
Exclusion Criteria:
Patients with diseases other than the 4 previously mentioned in inclusion criteria
Cardiovascular diseases care management in women will be compared to men in MEA countries according to current practice guidelines
Time frame: 2 months
Identify inequalities between both genders in terms of: • Healthcare insurance • Incomes • Access to healthcare
Time frame: 2 months
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.